The immunological features of HER2-negative BC with low-positive (1–9%) or intermediate-positive (10–50%) ER expression were investigated in a recent study, as compared to TNBC and tumors with high ER expression (>50%) [53]. This evidence concerns the gene ESR1 and breast cancer.